Ascendis Pharma A/S

NASDAQ:ASND

Biotechnology

Healthcare
$270.33 -0.02%

-$0.05 today

Market cap
$17.73B
Beta
0.39
P/E (TTM)
24.5
EPS (TTM)
$8.21
52W Low $160.86High $250.74

Volume 0.57M

Average 0.64M

ASND Common Stock Repurchased

Cash spent buying back the company's own shares.

Ascendis Pharma A/SNASDAQ: ASND

Common Stock Repurchased · Q3 FY2026 · quarter ended Sep 2026

Common stock repurchased growth accelerates

Q3 FY2026 common stock repurchased of €51M (cash outflow) rose 8569.4% year over year, ahead of the +766.7% change in trailing-twelve-month common stock repurchased. Sequentially, it fell 2.0% from the prior quarter. Over 3 fiscal years it compounded at -45.9% a year.

Context

  • Common stock repurchased amounted to 2.4% of revenue in FY2025, up 2.4 pp from a year earlier.
  • Common stock repurchased increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +8569.4% holds above the trailing-twelve-month pace of +766.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
-€51M-2.0% QoQ
Last fiscal yearDec 2025
-€16.71M— YoY
LTMSep 2026
-€155.87M+766.7% YoY
Common Stock Repurchased past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+8569.4%——
1 year———
3-year CAGR-45.9%——
5-year CAGR——
10-year CAGR——

Common Stock Repurchased history

EUR · from the cash flow

Latest · FY2025
(16.71M) EUR
Year-over-year change
—

Common Stock Repurchased vs competitors

How ASND compares with its peers on the latest reported figures

  • Peers report in different currencies, so common stock repurchased is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +766.7% is the 2nd highest of 7, against a peer median of +50.0%.
  • Common stock repurchased amounts to 12.9% of revenue for ASND, versus a peer median of 0.0%.
ASND Competitors
Common Stock Repurchased for ASND and competitors
Company Period LTM YoY 3-year CAGR% of revenue
UTHRUnited Therapeutics CorporationLTM Jun 2026$2.56B USD+365442.9%+344.3%81.1%
NBIXNeurocrine Biosciences, Inc.LTM Sep 2026$158.1M USD-66.2%—4.3%
ASNDAscendis Pharma A/SLTM Sep 2026€155.87M EUR+766.7%-45.9%12.9%
CORTCorcept Therapeutics IncorporatedLTM Jun 2026$96.22M USD-16.1%—11.6%
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026$38.78M USD+0.0%—0.0%
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$19.9M USD+139.8%+185.4%6.3%
INSMInsmed IncorporatedLTM Jun 2026$0 USD——0.0%
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$0 USD———
SEPNSepterna, Inc.LTM Sep 2026$0 USD+100.0%—0.0%
STOKStoke Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding ASND) —+50.0%+264.8%0.0%

Competitors are the stored peer set for ASND. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(383.58M)(583.19M)(481.45M)(378.08M)(219.03M)
Depreciation & Amortization15.39M17.96M18.91M17.71M17M
Deferred Income Tax(367K)5.38M7.3M4.84M3.21M
Stock-Based Compensation66.83M64.18M66.66M95.51M0
Change in Working Capital(47.72M)(12.47M)(99.79M)(107.16M)68.16M
Accounts Receivables(6.66M)(11.53M)(32.77M)(118.61M)14.97M
Inventory(75.41M)(55.27M)(78.26M)(86.68M)(5.69M)
Accounts Payables0000(9.96M)
Other Working Capital34.34M54.33M11.25M98.13M68.84M
Other Non-Cash Items(68.21M)12.45M21M60.98M182.44M
Operating Cash Flow(417.65M)(495.7M)(467.36M)(306.2M)51.77M
Capital Expenditures(24.23M)(14.49M)(2.44M)(1.43M)(8.15M)
Acquisitions (Net)(10.19M)0000
Purchases of Investments(226.04M)(213.84M)000
Sales of Investments149.88M280.53M07.35M0
Other Investing Activities(530K)9.54M288.92M950K0
Investing Cash Flow(110.58M)61.73M286.47M6.88M(8.15M)
Debt Repayment(6.43M)496.93M125.82M122.79M(21.09M)
Common Stock Issued367.88M00309.91M83.64M
Common Stock Repurchased(21.61M)(105.31M)(1.81M)0(16.71M)
Dividends Paid00000
Other Financing Activities11.54M5.15M10.29M11.22M(10.95M)
Financing Cash Flow351.39M396.77M134.29M443.93M34.89M
Effect of Forex Changes38.59M35.69M(6.01M)22.77M44.13M
Net Change in Cash(138.25M)(1.5M)(52.6M)167.38M122.65M
Free Cash Flow(441.88M)(510.19M)(469.8M)(307.62M)43.62M

Ascendis Pharma A/S

NASDAQ:ASND

Intrinsic Alpha fair value

Locked

Current Price

$270.33

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.